Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $32,003 | $50,200 |
| General and administrative | 14,089 | 14,991 |
| Total operating expenses | 46,092 | 65,191 |
| Loss from operations | (46,092) | (65,191) |
| Other income (expenses), net: | ||
| Interest and other income, net | 3,573 | 5,516 |
| Interest expense | (300) | (150) |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's R&D?
- Allogene Therapeutics (ALLO) reported R&D of $32M in Q1 2026.
- How has Allogene Therapeutics's R&D changed year-over-year?
- Allogene Therapeutics's R&D decreased by 36.2% year-over-year, from $50.2M to $32M.
- What is the long-term trend for Allogene Therapeutics's R&D?
- Over 4 years (2021 to 2025), Allogene Therapeutics's R&D has grown at a -9.1% compound annual growth rate (CAGR), from $220.18M to $150.15M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Allogene Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude